Release Date: 21/02/24 08:02 Summary: Half Year Financial Results Summary Price Sensitive: Yes Download Document 202.28KB Download
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%